Valdoxan (agomelatine) in the Treatment of Depression in Cerebrovascular Diseases (results of the Russian Resonance multicenter naturalistic study)
- 40 Downloads
The therapeutic efficacy and tolerance of Valdoxan (agomelatine) in the treatment of mild and moderate depression in cerebrovascular diseases (CVD) in routine neurological practice were evaluated. A total of eight Russian centers took part in the study. The study included 88 patients with CVD (18 men, 70 women) aged 40–65 (mean 55.4 ± 6.5) years. Treatment for six weeks eliminated depressive symptomatology in 81.20% of patients. Patients showed regression of fatigue, improvements in working efficiency, achievement of normal values for the coefficient of mental stability, and improvements in sleep.
Keywordsdepression cerebrovascular diseases Valdoxan agomelatine
Unable to display preview. Download preview PDF.
- 8.K. Krauchi, C. Cajochen, D. Mori, et al., “Early evening melatonin and S-20089 advance circadian phase and nocturnal regulation of core body temperature,” Am. J. Physiol., 272, 1178–1188 (1997).Google Scholar
- 9.R. Leproult, A. Van, Onderbergen, M. L’hermite-Baleriaux, et al., “Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men,” Clin. Endocrinol. (Oxf.), 63, 298–304 (2005).CrossRefGoogle Scholar
- 14.M. J. Millan, A. Gobert, F. Lejeune, et al., “The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways,” J. Pharmacol. Exp. Ther., 306, 954–964 (2003).PubMedCrossRefGoogle Scholar
- 23.O. van Reeth, L. Weibel, E. Olivares, et al., “Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus,” Am. J. Physiol. Regul. Integr. Comp. Physiol., 280, 1582–1591 (2001).Google Scholar